Possible Causes of Renal Failure in Disseminated TB on Anti-Koch's Treatment
The most likely cause of renal failure in a patient with disseminated tuberculosis receiving anti-TB therapy is rifampicin-induced acute interstitial nephritis (AIN), which occurs in approximately 1% of patients and typically develops 3-7 weeks after treatment initiation. 1
Drug-Induced Nephrotoxicity
Rifampicin-Induced Acute Interstitial Nephritis
- Rifampicin is the leading cause of acute kidney injury (AKI) during anti-TB treatment, accounting for the majority of drug-induced renal failure cases 1
- AIN typically presents with median onset at 45 days (range 21-54 days) after starting treatment 1
- Serum creatinine can rise dramatically from baseline (median 0.7 mg/dL) to peak levels of 4.0 mg/dL or higher 1
- Blood eosinophilia (>350 × 10⁹/L) is a significant risk factor for developing AKI during TB treatment 2
Other Anti-TB Drug Nephrotoxicity
- Pyrazinamide metabolites (pyrazinoic acid and 5-hydroxy-pyrazinoic acid) can accumulate and cause renal injury, particularly in patients with any degree of baseline renal impairment 3
- Ethambutol is 80% renally cleared and may accumulate, potentially contributing to nephrotoxicity 3
- Aminoglycosides (streptomycin, kanamycin, amikacin, capreomycin) used in drug-resistant cases are directly nephrotoxic 3
TB-Related Renal Complications
Direct TB Involvement
- Disseminated TB can directly involve the kidneys, causing genitourinary tuberculosis with renal parenchymal damage
- TB can cause immune complex-mediated glomerulonephritis, including crescentic glomerulonephritis, which presents with acute renal failure 4
- IgA nephropathy has been documented as a complication of disseminated TB, presenting with hematuria and red cell casts 5
Immune-Mediated Glomerular Disease
- Tuberculosis-associated glomerulonephritis is rare but can manifest as diffuse proliferative glomerulonephritis with crescent formation 4
- The mechanism involves immune complex deposition related to mycobacterial antigens producing an IgA immune response 5
Clinical Predictors and Risk Factors
High-Risk Features for AKI Development
- Advanced age (each year increases risk by 6%) 2
- Higher baseline eGFR paradoxically increases AKI risk (HR 1.04 per unit increase), possibly reflecting hyperfiltration or more aggressive drug dosing 2
- Elevated blood eosinophil count >350 × 10⁹/L (HR 10.99) strongly predicts AKI 2
- Baseline microalbuminuria, hematuria, elevated cystatin-C, and elevated CA-125 are predictive factors 6
- Low serum albumin is protective, possibly reflecting more conservative dosing in malnourished patients 6
Diagnostic Approach
Essential Investigations
- Serial serum creatinine monitoring to detect AKI early (defined by KDIGO criteria) 2
- Urinalysis for hematuria, proteinuria, and red cell casts to distinguish glomerular from interstitial disease 5, 6
- Blood eosinophil count as a marker of drug hypersensitivity 2
- Serum uric acid and hemoglobin levels, which are typically elevated at AKI onset 2
- Renal ultrasonography to exclude obstruction and assess for structural abnormalities 2
- Renal biopsy should be considered when diagnosis is uncertain, as it can definitively diagnose AIN or glomerulonephritis 1, 4
Management Considerations
Immediate Actions
- Stop all anti-TB drugs immediately when AKI is detected 1
- Administer corticosteroids for pathologically confirmed AIN (100% of cases) or clinically diagnosed AIN (43% of cases) 1
- Restart anti-TB treatment without rifampicin once renal function stabilizes, as 80% of patients achieve normalized renal function with this approach 1
Alternative Regimens
- Levofloxacin is the preferred alternative to rifampicin due to its safety profile and potency 1
- Dose adjustments are critical: For creatinine clearance <30 mL/min, pyrazinamide and ethambutol should be given three times weekly (not daily) at 25-35 mg/kg and 20-25 mg/kg respectively 3
- Rifampicin and isoniazid do not require dose adjustment as they are hepatically metabolized 3